Lenalidomide
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07072221CT.gov Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients | — | Recruiting | — | — | — |
NCT04447027CT.gov Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | — | Completed | — | — | — |
NCT04329130CT.gov Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | — | Unknown | — | — | — |
NCT05182957CT.gov Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma | — | Recruiting | — | — | — |
NCT04040491CT.gov PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | — | Unknown | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03547700CT.gov Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | — | Terminated | — | — | — |
NCT03302728CT.gov Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03011814CT.gov Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | — | Recruiting | — | — | — |
NCT02232516CT.gov Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT01075321CT.gov Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01116154CT.gov Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenalidomide (this asset) | The First Affiliated Hospital of Soochow University | Approved | BB · 66 |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for Lenalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 74 |
| Plasma Cell Neoplasm | — | P3 | BBB · 72 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenalidomide in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenalidomide-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →